GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Total Long-Term Assets

Lirum Therapeutics (Lirum Therapeutics) Total Long-Term Assets : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Lirum Therapeutics's Total Long-Term Assets for the quarter that ended in Dec. 2023 was $0.00 Mil.


Lirum Therapeutics Total Long-Term Assets Historical Data

The historical data trend for Lirum Therapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Total Long-Term Assets Chart

Lirum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Total Long-Term Assets
- - -

Lirum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Sep23 Dec23
Total Long-Term Assets - - - - -

Lirum Therapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


Lirum Therapeutics Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Lirum Therapeutics (Lirum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
590 Madison Avenue, 21st Floor, New York, NY, USA, 10022
Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines